Skip to main content

Lisa M. Bloudek, PharmD, MS

Senior Partner and CEO
Curta
Seattle, WA
Senior Partner and CEO, Curta, Seattle, WA
Authored Items
Budget Impact of Intravenous Cetirizine Hydrochloride for the Treatment of Acute Urticaria in the Emergency Department Setting
Lisa M. Bloudek, PharmD, MS, LoAn K. Ho, PharmD, Neha Kapur, PharmD, Lonnie D. Brent, PharmD
September 2022 Vol 15, No 3 in Business, Original Research
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia
David Campbell, PharmD, MS, James T. Kenney, RPh, MBA, Marlo Blazer, PharmD, BCOP, Lisa M. Bloudek, PharmD, MS, John Brokars, MS, Dinara Makenbaeva, MD, MBA
November 2019 Vol 12, No 7 in Business, Original Research
Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors
Lisa M. Bloudek, PharmD, MS, Gary Branning, MBA, Dinara Makenbaeva, MD, MBA, Michael Eaddy, PharmD, PhD
December 2015 Vol 8, No 9 in Business, Original Research
Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework
James T. Kenney, RPh, MBA, Anuja Roy, PhD, MBA, Jonathan K. Kish, PhD, MPH, Lisa M. Bloudek, PharmD, MS, David S. Siegel, MD, PhD, Sundar Jagannath, MD, Denise Globe, PhD, Emil T. Kuriakose, MD, Kristen Migliaccio-Walle, BS
June 2015, Vol 8, No 4 in Business
Last modified: September 28, 2022